Is Monopar Therapeutics financially healthy?
Not really
Monopar Therapeutics carries heavy debt: it would take 2,923.7 years of earnings to pay it off.
The numbers behind it
Net debt / EBITDA2,923.7 years
Cash vs. debt$62M vs. $154,920
Current ratio51.4×Short-term assets for each $1 of bills due within a year
How we decide
We measure debt in years of earnings (net debt / EBITDA): under 1 is very comfortable, 1 to 3 is manageable, above 3 is heavy. A company that earns less than 3 times its interest bill also counts as weak.
More questions about Monopar Therapeutics
Data as of Nov 13, 2026.